Abstract
The biological behavior of osteosarcoma in dogs is similar to that in humans and the dog has been suggested as a model for the disease in humans. Because occult metastatic disease is common at presentation, systemic therapy is necessary. The dihydropyridine, dexniguldipine hydrochloride (B859-35), is a potent inhibitor of protein-kinase-C(PKC)-stimulated cell proliferation and has shown therapeutic activity in experimentally induced neuroendocrine hamster lung tumors and in a mammary cancer cell line. In human osteosarcoma cell lines, PKC activity can be down-regulated, resulting in increased sensitivity to cisplatin. Since these results supported the involvement of PKC inhibitors in the therapeutic management of osteosarcoma, we performed a prospective, randomized clinical trial using dogs with naturally occurring appendicular osteosarcoma to determine the therapeutic potential of dexniguldipine. Dogs received either no drug treatment (control group,n=8), standard treatment (e.g., cisplatin,n=14), or dexniguldipine treatment (n=14) following amputation. Dexniguldipine-and cisplatin-treated dogs had a longer median remission duration and survival time than untreated dogs (P<0.05); however, dexniguldipine-treated dogs had a shorter survival time than cisplatin-treated dogs (P<0.05). The results of this study demonstrate that dexniguldipine has significant activity in the inhibition of canine osteosarcoma micrometastases. The identification of a tumor model that may be responsive to this class of antiproliferative agents warrants further clinical investigation to determine the optimum dosage of dexniguldipine and the role it may have in the therapeutic management of canine osteosarcoma.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Brodey RS (1979) The use of naturally occurring cancer in domestic animals for research into human cancer: general considerations and a review of canine skeletal osteosarcoma. Yale J Biol Med 52:345–361
Gietzen K, Bai G, Abdalla F (1990) Selective inhibition of proliferation by a novel dihydropyridine derivative with anticalmodulin activity in the mammary tumor cell line ZR75-1. Med Sci Res 18:627–629
Hahn KA, Richardson RC (1995) Clinical staging. In: Hahn KA, Richardson RC (eds) Cancer chemotherapy. A veterinary handbook. Williams & Wilkins, Philadelphia, pp 238–239
Hahn KA, Hurd C, Cantwell HD (1990) Single phase methylene diphosphate bone scinitigraphy in the diagnostic evaluation of dogs with osteosarcoma. J Am Vet Med Assoc 196:1483–1486
Hahn KA, Bravo L, Adams WH, Frazier DL (1994) Naturally occurring tumors in dogs as comparative models for cancer therapy research. In Vivo 8:133–144
Henderson RA, Brawner WR, Brewer WG, Henry CJ (1995) Clinical staging. In: Hahn KA, Richardson RC (eds) Cancer chemotherapy. A veterinary handbook. Williams & Wilkins, Philadelphia, pp 23–45
Jaffe N, Raymond AK, Ayala A, Carrasco CH, Wallace S, Robertson R, Griffiths M, Wang YM (1989) Effect of cumulative courses of intra-arterialcis-diamminodichloroplatinum-II on the primary tumor in osteosarcoma. Cancer 63:63–67
Knapp DW, Richardson RC, Bonney PL, Hahn KA (1988) Cisplatin therapy in 41 dogs with malignant tumors. J Vet Int Medicine 2:41–46
Lamb CR, Berg J, Bengtson AE (1990) Preoperative measurement of canine primary bone tumors, using radiography and bone scintigraphy. J Am Vet Med Assoc 196:1474–1478
Malawer MM, Link MP, Donaldson SS (1993) Sarcomas of bone. In: Devita VT, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology. Lippincott, Philadelphia, pp 1509–1566
Mankin HJ, Willet CG, Harmon DC (1991) Malignant tumors of bone. In: Holleb AI, Fink DJ, Murphy GP (eds) American Cancer Society textbook of clinical oncology. American Cancer Society Inc, Atlanta, pp 355–358
Mauldin GN, Matus RE, Withrow SJ, Patnaik AK (1988) Canine osteosarcoma: treatment by amputation versus amputation and adjuvant chemotherapy using doxorubicin and cisplatin. J Vet Int Med 2:177–180
Misdorp W, Hart AAM (1979) Some prognostic and epidemiologic factors in canine osteosarcoma. J Natl Can Inst 62:537–545
O'Brien MG, Withrow SJ, Straw RC (1993) Recent advances in the treatment of canine appendicular osteosarcoma. Comp Cont Educ Small Anim Pract 15:939–948
Perego P, Casati G, Gambetta RA, Soranzo C, Zunino F (1993) Effect of modulation of protein kinase C activity on cisplatin cytotoxicity in cisplatin-resistant and cisplatin-sensitive human osteosarcoma cells. Cancer Lett 72:53–58
Schuller HM, Orloff M (1994) Inhibition of protein kinase C-dependent cell proliferation in human lung cancer cell lines by the dihydropyridine dexniguldipine. J Cancer Res Clin Oncol 120:354–358
Schuller HM, Becker KL, Witschi H-P (1988) An animal model for neuroendocrine lung cancer. Carcinogenesis 7:293–296
Spodnick GJ, Berg J Rand WM, Schelling SH, Couto G, Harvey HJ, Henderson RA, MacEwen EG, Mauldin N, McCaw DL, Moore AS, Morrison W, Norris AM, O'Bradovich J, O'Keefe DA, Page R, Ruslander D, Klausner J, Straw R, Thompson JP, Withrow SJ (1992) Prognosis for dogs with appendicular osteosarcoma treated by amputation alone: 162 cases (1978–1988). J Am Vet Med Assoc 200:995–1000
Thompson JP, Fugent MJ (1992) Evaluation of survival times after limb amputation, with or without subsequent administration of cisplatin, for treatment of appendicular osteosarcoma in dogs: 30 cases (1979–1990). J Am Vet Med Assoc 200:531–534
Thompson JP, Fugent MJ (1992) Evaluation of survival times after limb amputation, with or without subsequent administration of cisplatin, for treatment of appendicular osteosarcoma in dogs: 30 cases (1979–1990). J Am Vet Med Assoc 200:531–534
Uberall F, Maly K, Egle a, Doppler W, Hoffman T, Grunicke HH (1991) Inhibition of cell proliferation, protein kinase C, and phorbolester-induced for expression by the dihydropyridine derivative B859-35. Cancer Res 51:5821–5825
Weinstein IB (1983) Tumor promoters, protein kinase C, phospholipid, and control of growth. Nature 302:250
Withrow SJ, Powers BE, Straw RC, Wilkins RM (1991) Comparative aspects of osteosarcoma: dog vs. man. Clinical Orthop 270:159–167
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hahn, K.A., Legendre, A.M. & Schuller, H.M. Amputation and dexniguldipine as treatment for canine appendicular osteosarcoma. J Cancer Res Clin Oncol 123, 34–38 (1997). https://doi.org/10.1007/BF01212612
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01212612